Discovery of a Highly Potent, Orally Active Mitosis/Angiogenesis Inhibitor R1530 for the Treatment of Solid Tumors

被引：20

作者：

Liu, Jin-Jun ^{[1
]}

Higgins, Brian ^{[2
]}

Ju, Grace ^{[2
]}

Kolinsky, Kenneth ^{[2
]}

Luk, Kin-Chun ^{[1
]}

Packman, Kathryn ^{[2
]}

Pizzolato, Giacomo ^{[1
]}

Ren, Yi ^{[3
]}

Thakkar, Kshitij ^{[1
]}

Tovar, Christian ^{[2
]}

Zhang, Zhuming ^{[1
]}

Woykulich, Peter M. ^{[1
]}

机构：

[1] Hoffmann La Roche Inc, Discovery Chem, Nutley, NJ 07110 USA

[2] Hoffmann La Roche Inc, Discovery Oncol, Nutley, NJ 07110 USA

[3] Hoffmann La Roche Inc, Chem Synth, Nutley, NJ 07110 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 02期

关键词：

pyrazolobenzodiazepines; mitosis/angiogenesis inhibitor; antitumor effect; VGFr-2; FGFr and PDGFr-beta; ORTHO-SUBSTITUTION-REACTION; ORGANIC-SYNTHESIS; ANGIOGENESIS; CANCER; AMINOHALOBORANE; COMBINATION; THERAPY;

D O I：

10.1021/ml300351e

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A new series of 7,8-disubstituted pyrazolobenzodiazepines based on the lead compound 1 have been synthesized and evaluated for their effects on mitosis and angiogenesis. Described herein is the design, synthesis, SAR, and antitumor activity of these compounds leading to the identification of R1530, which was selected for clinical evaluation.

引用

页码：259 / 263

页数：5

共 50 条

[21] R-85355 - A POTENT, ORALLY ACTIVE 5-LIPOXYGENASE INHIBITOR
BEETENS, JR
BEERENS, D
VANAMMEL, K
SOMERS, Y
LOOTS, W
DECLERCK, F
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1991, 419 (01): : R3 - R3
[22] Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid Tumors
Mahajan, Dinesh
Sen, Somdutta
Kuila, Bilash
Sharma, Amit
Arora, Reena
Sagar, Milind
Mahapatra, Amal Ray
Gawade, Lalita Babasaheb
Dugar, Sundeep
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11121 - 11130
[23] FK-906, A HIGHLY POTENT, ORALLY-ACTIVE HUMAN RENIN INHIBITOR
NEYA, M
MARUSAWA, H
IMAL, K
KAYAKIRI, N
WATANABE, S
HEMML, K
HASHIMOTO, M
TANAKA, H
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 206 : 56 - MEDI
[24] Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors
Duan, Yingchao
Yu, Tong
Jin, Linfeng
Zhang, Shaojie
Shi, Xiaojing
Zhang, Yizhe
Zhou, Nanqian
Xu, Yongtao
Lu, Wenfeng
Zhou, Huimin
Zhu, Huijuan
Bai, Suping
Hu, Kua
Guan, Yuanyuan
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 254
[25] COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors
Panchal, Anand
Seto, Pui
Wall, Russell
Hillier, Brian J.
Zhu, Ying
Krakow, Jessica
Datt, Aakash
Pongo, Elizabeth
Bagheri, Andisheh
Chen, Tseng-Hui T.
Degenhardt, Jeremiah D.
Culp, Patricia A.
Dettling, Danielle E.
Vinogradova, Maia V.
May, Chad
DuBridge, Robert B.
MABS, 2020, 12 (01)
[26] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
Johnson, Douglas S.
Stiff, Cory
Lazerwith, Scott E.
Kesten, Suzanne R.
Fay, Lorraine K.
Morris, Mark
Beidler, David
Liimatta, Marya B.
Smith, Sarah E.
Dudley, David T.
Sadagopan, Nalini
Bhattachar, Shobha N.
Kesten, Stephen J.
Nomanbhoy, Tyzoon K.
Cravatt, Benjamin F.
Ahn, Kay
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (02): : 91 - 96
[27] Discovery of ITX 4520: A highly potent orally bioavailable hepatitis C virus entry inhibitor
Mittapalli, Gopi Kumar
Zhao, Fang
Jackson, Andrew
Gao, Hongfeng
Lee, Haekyung
Chow, Stephine
Kaur, Maninder Pal
Natalie Nguyen
Zamboni, Robert
McKelvy, Jeffrey
Wong-Staal, Flossie
Macdonald, James E.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (15) : 4955 - 4961
[28] Small Molecule R1498 as a Well-Tolerated and Orally Active Kinase Inhibitor for Hepatocellular Carcinoma and Gastric Cancer Treatment via Targeting Angiogenesis and Mitosis Pathways
Zhang, Chao
Wu, Xihan
Zhang, Meifang
Zhu, Liangcheng
Zhao, Rong
Xu, Danqing
Lin, Zhaohu
Liang, Chungen
Chen, Taiping
Chen, Li
Ren, Yi
Zhang, Joe
Qin, Ning
Zhang, Xiongwen
PLOS ONE, 2013, 8 (06):
[29] DISCOVERY OF A NOVEL AND POTENT CHOLESTEROL ABSORPTION INHIBITOR AS PROMISING ORALLY ACTIVE LIPID LOWERING DRUG
Kanou, M.
Nishiwaki, Y.
Nakano, A.
Yamanaka, Y.
ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 79 - 79
[30] Discovery of a Novel, Potent, Orally Active, and Safe Inhibitor Targeting Human Mitochondrial RNA Polymerase
Li, Xinnan
Ze, Xiaotong
Zhou, Shengnan
Hu, Zhaoxin
He, Chen
Jia, Yilin
Liu, Lihua
Wang, Tao
Li, Junda
Xu, Shengtao
Yang, Dong-Hua
Chen, Zhe-Sheng
Yao, Hequan
Xu, Jinyi
Yao, Hong
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) : 5118 - 5153

← 1 2 3 4 5 →